C Richer

1.0k total citations
46 papers, 737 citations indexed

About

C Richer is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Physiology. According to data from OpenAlex, C Richer has authored 46 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 13 papers in Molecular Biology and 10 papers in Physiology. Recurrent topics in C Richer's work include Renin-Angiotensin System Studies (8 papers), Eicosanoids and Hypertension Pharmacology (7 papers) and Protein Hydrolysis and Bioactive Peptides (7 papers). C Richer is often cited by papers focused on Renin-Angiotensin System Studies (8 papers), Eicosanoids and Hypertension Pharmacology (7 papers) and Protein Hydrolysis and Bioactive Peptides (7 papers). C Richer collaborates with scholars based in France, Belgium and United Kingdom. C Richer's co-authors include J. F. Giudicelli, Giudicelli Jf, Alain Berdeaux, Christian Thuillez, Icilio Cavero, S. Glasson, Jean‐Louis Freslon, Paul Mulder, J. Pratz and S. Mondot and has published in prestigious journals such as Hypertension, Journal of Pharmacology and Experimental Therapeutics and Trends in Pharmacological Sciences.

In The Last Decade

C Richer

43 papers receiving 669 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C Richer France 16 395 231 119 117 86 46 737
Bühler Fr Switzerland 14 320 0.8× 199 0.9× 132 1.1× 155 1.3× 63 0.7× 75 707
A. Van de Water Belgium 13 651 1.6× 386 1.7× 43 0.4× 112 1.0× 64 0.7× 24 959
Giudicelli Jf France 12 256 0.6× 122 0.5× 56 0.5× 87 0.7× 44 0.5× 77 543
Kathleen McLean United Kingdom 13 307 0.8× 228 1.0× 97 0.8× 98 0.8× 69 0.8× 22 692
Yumi Katano Japan 18 385 1.0× 335 1.5× 91 0.8× 210 1.8× 91 1.1× 64 889
H.‐J. Mest Germany 12 152 0.4× 138 0.6× 173 1.5× 73 0.6× 68 0.8× 61 559
Pierre Schiavi France 14 311 0.8× 125 0.5× 119 1.0× 90 0.8× 26 0.3× 23 557
István Leprán Hungary 20 548 1.4× 370 1.6× 51 0.4× 123 1.1× 126 1.5× 52 964
Robert L. Wendt United States 14 310 0.8× 194 0.8× 63 0.5× 87 0.7× 123 1.4× 33 615
Philip J. Privitera United States 16 188 0.5× 138 0.6× 69 0.6× 77 0.7× 126 1.5× 38 613

Countries citing papers authored by C Richer

Since Specialization
Citations

This map shows the geographic impact of C Richer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Richer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Richer more than expected).

Fields of papers citing papers by C Richer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Richer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Richer. The network helps show where C Richer may publish in the future.

Co-authorship network of co-authors of C Richer

This figure shows the co-authorship network connecting the top 25 collaborators of C Richer. A scholar is included among the top collaborators of C Richer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Richer. C Richer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Belaïdi, Elise, Loubina Fazal, Maud Clemessy, et al.. (2015). Tissue kallikrein is required for the cardioprotective effect of Cyclosporin A in myocardial ischemia in the mouse. Biochemical Pharmacology. 94(1). 22–29. 8 indexed citations
2.
Griol‐Charhbili, Violaine, et al.. (2008). CARDIOPROTECTION AND KALLIKREIN–KININ SYSTEM IN ACUTE MYOCARDIAL ISCHAEMIA IN MICE. Clinical and Experimental Pharmacology and Physiology. 35(4). 489–493. 25 indexed citations
3.
Pons, Sandrine, et al.. (2003). Survival, haemodynamics and cardiac remodelling follow up in mice after myocardial infarction. Clinical and Experimental Pharmacology and Physiology. 30(1-2). 25–31. 13 indexed citations
4.
Richer, C, et al.. (2001). Coronary Dilatation Reserve In Experimental Hypertension And Chronic Heart Failure: Effects Of Blockade Of The Renin–Angiotensin System. Clinical and Experimental Pharmacology and Physiology. 28(12). 997–1001. 5 indexed citations
5.
Levasseur, Régis, C. Le Goff, C Richer, et al.. (1999). Amylose AA compliquant une sarcoïdose. La Revue de Médecine Interne. 20(2). 168–170. 4 indexed citations
6.
7.
Richer, C, et al.. (1998). Comparison of the haemodynamic actions of desflurane/N2O and isoflurane/N2O anaesthesia in vascular surgical patients. Acta Anaesthesiologica Scandinavica. 42(9). 1057–1062. 6 indexed citations
8.
Richer, C, et al.. (1997). Antihypertensive Drugs in the Stroke-Prone Spontaneously Hypertensive Rat. Clinical and Experimental Hypertension. 19(5-6). 925–936. 14 indexed citations
9.
Richer, C, J.G. Gobert, Michel Noyer, Ernst Wülfert, & Giudicelli Jf. (1996). Peripheral α2‐adrenoceptor‐mediated sympathoinhibitory effects of mivazerol. Fundamental and Clinical Pharmacology. 10(6). 529–537. 3 indexed citations
10.
Richer, C, et al.. (1995). Are vasopressin peripheral V1 receptors involved in the development of malignant hypertension and stroke in SHR‐SPs?. Fundamental and Clinical Pharmacology. 9(5). 469–478. 3 indexed citations
11.
Thuillez, Christian, et al.. (1991). Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.. British Journal of Clinical Pharmacology. 31(1). 33–39. 8 indexed citations
12.
Richer, C, et al.. (1990). Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sciences. 47(19). 1693–1705. 89 indexed citations
13.
Giudicelli, Jean & C Richer. (1990). [Potassium channel activators: from pharmacology to therapeutics].. PubMed. 44(6). 419–30. 2 indexed citations
14.
Richer, C, et al.. (1989). [Potassium agonists: regional vasodilator profile in rats].. PubMed. 82(7). 1333–7. 6 indexed citations
15.
Richer, C, Christian Thuillez, & J. F. Giudicelli. (1987). Perindopril, Converting Enzyme Blockade, and Peripheral Arterial Hemodynamics in the Healthy Volunteer. Journal of Cardiovascular Pharmacology. 9(1). 94–102. 39 indexed citations
16.
Vanhoutte, Paul M., Stephen G. Ball, Alain Berdeaux, et al.. (1986). Mechanism of action of ketanserin in hypertension. Trends in Pharmacological Sciences. 7. 58–59. 27 indexed citations
17.
Cavero, Icilio, et al.. (1984). Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.. Journal of Pharmacology and Experimental Therapeutics. 228(3). 779–791. 22 indexed citations
18.
Giudicelli, J. F., Alain Berdeaux, Edouard Auvinet, et al.. (1984). Attenuation by diltiazem of arterial baroreflex sensitivity in man. European Journal of Clinical Pharmacology. 26(6). 675–679. 22 indexed citations
19.
Jf, Giudicelli, Christian Thuillez, C Richer, et al.. (1980). Beta‐adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.. British Journal of Clinical Pharmacology. 10(1). 41–49. 48 indexed citations
20.
Richer, C, et al.. (1979). β-Adrenoceptor blocking drugs, heart rate and genetic hypertension development in rats. Cellular and Molecular Life Sciences. 35(5). 656–657. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bühler Fr Breakdown of academic impact, for papers by A. Van de Water Breakdown of academic impact, for papers by Giudicelli Jf Breakdown of academic impact, for papers by Kathleen McLean Breakdown of academic impact, for papers by Yumi Katano Breakdown of academic impact, for papers by H.‐J. Mest Breakdown of academic impact, for papers by Pierre Schiavi Breakdown of academic impact, for papers by István Leprán Breakdown of academic impact, for papers by Robert L. Wendt Breakdown of academic impact, for papers by Philip J. Privitera
Rankless by CCL
2026